Abstract:Gene therapy has long held promise to correct a variety of human diseases and defects. Discovery of the Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR), the mechanism of the CRISPR-based prokaryotic adaptive immune system (CRISPR-associated system, Cas), and its repurposing into a potent gene editing tool has revolutionized the field of molecular biology and generated excitement for new and improved gene therapies. Additionally, the simplicity and flexibility of the CRISPR/Cas9 site-specific nuclease system has led to its widespread use in many biological research areas including development of model cell lines, discovering mechanisms of disease, identifying disease targets, development of transgene animals and plants, and transcriptional modulation. In this review, we present the brief history and basic mechanisms of the CRISPR/Cas9 system and its predecessors (ZFNs and TALENs), lessons learned from past human gene therapy efforts, and recent modifications of CRISPR/Cas9 to provide functions beyond gene editing. We introduce several factors that influence CRISPR/Cas9 efficacy which must be addressed before effective in vivo human gene therapy can be realized. The focus then turns to the most difficult barrier to potential in vivo use of CRISPR/Cas9, delivery. We detail the various cargos and delivery vehicles reported for CRISPR/Cas9, including physical delivery methods (e.g. microinjection; electroporation), viral delivery methods (e.g. adeno-associated virus (AAV); full-sized adenovirus and lentivirus), and non-viral delivery methods (e.g. liposomes; polyplexes; gold particles), and discuss their relative merits. We also examine several technologies that, while not currently reported for CRISPR/Cas9 delivery, appear to have promise in this field. The therapeutic potential of CRISPR/Cas9 is vast and will only increase as the technology and its delivery improves.

Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy

Delivery of CRISPR/Cas9 by novel strategies for gene therapy.

Progress of delivery methods for CRISPR-Cas9

Delivering CRISPR: a review of the challenges and approaches

Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation

Non-viral and Viral Delivery Systems for CRISPR-Cas9 Technology in the Biomedical Field

Delivery of CRISPR/Cas9 for Therapeutic Genome Editing

CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications

Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for in Vivo CRISPR/Cas-Based Genome Editing.

Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

CRISPR/Cas Systems: Delivery and Application in Gene Therapy

[Advances of Cas9/sgRNA delivery system for gene editing].

Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy

Delivery and Application Progresses of CRISPR/Cas Gene Editing System

Intelligent nanotherapeutic strategies for the delivery of CRISPR system

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing

CRISPR/Cas Gene Editing and Delivery Systems for Cancer Therapy

CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles